Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis

• Conditions: Lung Disease; Pneumonia; Respiratory Tract Diseases; Hemorrhage; Tuberculosis; Bronchiectasis; Bronchitis; Pathologic Processes; Mycosis; Hemoptysis

• Registration Number: NCT02913365
• Lead Sponsor: Université de Sherbrooke

Brief Summary

The study consist of a retrospective analysis of the etiologies, investigations and outcomes of patients presenting between 2005 to 2010 with hemoptysis in a North-American Tertiary center.

Detailed Description

RATIONALE:

Hemoptysis, mild or massive, is worrisome for both patients and physicians. The management is different depending on the causes, which are not well defined for the North American population. Despite the fact that this symptom is commonly reported in clinic, there are only a few studies published on this subject in the North-American population. Tuberculosis was a frequent cause of hemoptysis described in populations overseas, which seems less prevalent in the investigators center.

Also, there are no known official guidelines regarding the investigation and management of hemoptysis. The investigators hypothesized that the use of modern technology in a North American population may result in different findings and provide a more accurate diagnostic approach.

Therefore, the study compares the different etiologies of hemoptysis and investigation modalities used in patients presenting in a North-American tertiary center.

METHOD:

The investigators did a retrospective analysis of medical chart from patients with hemoptysis who visited the investigators center between 2005 and 2010. Each visit has been reviewed individually to describe the characteristics of patients, etiologies of hemoptysis and investigation modalities used. All-cause mortality at 2 years was also recorded.

Descriptive statistical analyses will conducted on the data available.

Study Timeline

• Study Start: 2012-10
• Status Verified: 2016-09
• Study First Submitted: 2016-09-15
• Study First Submitted QC: 2016-09-22
• Last Update Submitted: 2016-09-22
• Study First Posted: 2016-09-23
• Last Update Posted: 2016-09-23
• Primary Completion: 2017-06
• Study Completion: 2017-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

Any patient over the age of 18 presenting with:

• A diagnosis of hemoptysis on an outpatient basis.
• A diagnosis of hemoptysis during consultation in the emergency department.
• A diagnosis of hemoptysis on the admission sheet.
• A diagnosis of hemoptysis when hospitalized.
• A complication of hemoptysis
• Hemoptysis on the report of the bronchoscopy, chest computed tomography, pulmonary angiography, ventilation-perfusion single-photon emission computed tomography or blood transfusion.

Exclusion Criteria

• Patients under 18 years of age.
• Patient who refused investigation for hemoptysis.
• Incomplete medical chart

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Etiologies of hemoptysis	5 years	Defining the prevalence of pulmonary diseases by measuring the percentage of patients presenting with hemoptysis caused by lung cancer, bronchiectasis, pulmonary embolism, arteriovenous fistula, pneumonia, bronchitis, tuberculosis, mycosis, heart failure, pseudohemoptysis, cryptogenic and other causes.

Secondary Outcome Measures

Name	Time	Method
Sensitivity of chest X-ray, chest CT-scan and CT-angiography, bronchoscopy, ventilation-perfusion with single-photon emission computed tomography and pulmonary angiography.	5 years	Determining the sensitivity in obtaining the etiology of the hemoptysis episode of each diagnostic modality that follows : chest X-ray, chest CT-scan and CT-angiography, bronchoscopy, ventilation-perfusion with single-photon emission computed tomography and pulmonary angiography in the diagnosis of different etiologies of hemoptysis.
All-cause mortality at 2 years	2 years	All-cause mortality at 2 years after the diagnosis of hemoptysis.
Smoking status	Day 1	Determining the percentage of patients who : never smoked, is an active smoker, former smoker or unknown status.
Age	Day 1	Determining the average age of the enrolled patients.
Gender	Day 1	Determining the percentage of each gender of the enrolled patients.
International Normalized Ratio	Day 1	Determining the median of the international normalized ratio (INR).
Partial Thromboplastin Time	Day 1	Determining the median of the partial thromboplastin time (PTT).
Platelet count	Day 1	Determining the average of the platelet count measured per microliter of blood.

Trial Locations

Locations (1)

Centre Hospitalier Universitaire de Sherbrooke; 🇨🇦 Sherbrooke, Quebec, Canada